Correction: Procollagen-lysine 2-oxoglutarate 5-dioxygenase 2 promotes hypoxia-induced glioma migration and invasion

Yangyang Xu; Lin Zhang; Yuzhen Wei; Xin Zhang; Ran Xu; Mingzhi Han; Bing Huang; Anjing Chen; Wenjie Li; Qing Zhang; Gang Li; Jian Wang; Peng Zhao; Xingang Li

doi:10.18632/oncotarget.28003

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Corrections:

Correction: Procollagen-lysine 2-oxoglutarate 5-dioxygenase 2 promotes hypoxia-induced glioma migration and invasion

PDF | How to cite

Oncotarget. 2021; 12:1442-1443. https://doi.org/10.18632/oncotarget.28003

Metrics: PDF 1064 views | ?

Yangyang Xu¹, Lin Zhang², Yuzhen Wei^1,3, Xin Zhang¹, Ran Xu¹, Mingzhi Han¹, Bing Huang¹, Anjing Chen¹, Wenjie Li¹, Qing Zhang¹, Gang Li¹, Jian Wang^1,4, Peng Zhao¹ and Xingang Li¹

¹ Department of Neurosurgery, Qilu Hospital of Shandong University and Brain Science Research Institute, Shandong University, Jinan 250012, China
² Institute of Basic Medical Sciences, Qilu Hospital of Shandong University, Jinan 250012, China
³ Department of Neurosurgery, Jining No.1 People’s Hospital, Jining 272011, China
⁴ Department of Biomedicine, University of Bergen, 5009 Bergen, Norway

Published: July 06, 2021

Copyright: © 2021 Xu et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has been corrected: Due to errors during the assembly of Figure 5B, incorrect images were placed in row 1, panel 4 and row 2, panel 4. The corrected Figure 5B, produced using the original data, is shown below. The authors declare that these corrections do not change the results or conclusions of this paper.

Original article: Oncotarget. 2017; 8:23401–23413. DOI: https://doi.org/10.18632/oncotarget.15581.

Figure 5: Treatment with FAK inhibitor attenuates U87 and U251 cell migration and invasion. (B) Representative images and quantification (cell number/field) of transwell migration assays for parental U87 and U251 cells treated with TAE226 (5 μM) under normoxic and hypoxic conditions (Scale bars, 50 μm).

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 28003

Publication Alerts

Post-Publication Promotion

Corrections:

Correction: Procollagen-lysine 2-oxoglutarate 5-dioxygenase 2 promotes hypoxia-induced glioma migration and invasion